Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Inclisiran in dyslipidemia
Drugs Today (Barc). 2021 May;57(5):311-319. doi: 10.1358/dot.2021.57.5.3277083.ABSTRACTCardiovascular disease (CVD) is the leading cause of death worldwide. Hypercholesterolemia has been shown to be one of the most important risk factors for CVD. Statins are currently the standard of care for the management of hypercholesterolemia. However, certain patients on statin therapy fail to achieve the desired low-density lipoprotein cholesterol (LDL-C) goals or are intolerant to statins due to side effects (mostly myalgias). The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the subsequent development of P...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: C E Kosmas A Mu ñoz Estrella A Sourlas D Pantou Source Type: research

Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder
Drugs Today (Barc). 2021 May;57(5):321-336. doi: 10.1358/dot.2021.57.5.3265453.ABSTRACTUntil recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: N Siebert A Duchow F Paul C Infante-Duarte J Bellmann-Strobl Source Type: research

Remimazolam: a short-acting benzodiazepine for procedural sedation
Drugs Today (Barc). 2021 May;57(5):337-346. doi: 10.1358/dot.2021.57.5.3264119.ABSTRACTThe ultra-short-acting opioid analgesic remifentanil provided the approach that was used in the synthesis of remimazolam. A carboxylic ester was incorporated into the benzodiazepine structure providing a resultant compound that is rapidly broken down in the body into a breakdown product that is inactive, thus ensuring a very short-acting benzodiazepine. Remimazolam is highly selective in its action, only having activity at the GABAA receptor. It has been shown to be highly effective in providing sedation for bronchoscopy and colonoscopy ...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: D M Paton Source Type: research

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification
Drugs Today (Barc). 2021 May;57(5):347-357. doi: 10.1358/dot.2021.57.5.3266244.ABSTRACTPsoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Disease modification could be ach...
Source: Drugs of Today - June 1, 2021 Category: Drugs & Pharmacology Authors: S Magina P Filipe Source Type: research

Update on nifurtimox for treatment of Chagas disease
Drugs Today (Barc). 2021 Apr;57(4):251-263. doi: 10.1358/dot.2021.57.4.3251712.ABSTRACTChagas disease is a vector-borne neglected tropical disease caused by Trypanosoma cruzi. It is a systemic and chronic parasitic infection which is endemic in 21 countries with 10 million cases worldwide and 12,000 annual deaths. Around 70 million people in the Americas are at risk of contracting this disease, and less than 1% of infected people are treated due to low disease awareness and limited access to treatment. The current treatment for Chagas disease consists of benznidazole and nifurtimox under the World Health Organization (WHO)...
Source: Drugs of Today - April 14, 2021 Category: Drugs & Pharmacology Authors: R Thakare A Dasgupta S Chopra Source Type: research

Tepotinib hydrochloride for the treatment of non-small cell lung cancer
Drugs Today (Barc). 2021 Apr;57(4):265-275. doi: 10.1358/dot.2021.57.4.3238323.ABSTRACTNon-small cell lung cancer (NSCLC) is one of the most devastating cancers with high mortality worldwide. By inhibiting the activity of specific molecular targets in the cancer cells, tyrosine kinase inhibitors (TKIs) have become a standard treatment in combating NSCLC. Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. Tepotinib demonstrated durable clinical response in phase II clinical trials, which led to its appro...
Source: Drugs of Today - April 14, 2021 Category: Drugs & Pharmacology Authors: Z-X Wu J Li S Dong L Lin C Zou Z-S Chen Source Type: research

Tirabrutinib hydrochloride for B-cell lymphomas
Drugs Today (Barc). 2021 Apr;57(4):277-289. doi: 10.1358/dot.2021.57.4.3264113.ABSTRACTBruton tyrosine kinase (BTK) plays an important role in the B-cell receptor (BCR) signaling pathway by mediating proliferation, migration and adhesion in B-cell malignancies. Therefore, the components of BCR signaling, especially BTK, are considered to be attractive therapeutic targets. Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of several types of B-cell malignancies worldwide. However, ibrutinib has off-target activities on non-BTK kinase that are related to adverse effects or might translate into cl...
Source: Drugs of Today - April 14, 2021 Category: Drugs & Pharmacology Authors: W Munakata K Tobinai Source Type: research

Superior antihypertensive and cardioprotective effects of chlorthalidone compared with hydrochlorothiazide
Drugs Today (Barc). 2021 Apr;57(4):291-301. doi: 10.1358/dot.2021.57.4.3266245.ABSTRACTDiuretics are the most commonly used drugs for the treatment of hypertension, either alone or in combination with other antihypertensive drugs. Of all diuretics, hydrochlorothiazide (HCTZ) and chlorthalidone (CTD) are the most commonly used, with HCTZ being the most widely prescribed diuretic. Recent studies have shown that CTD is a better diuretic with superior antihypertensive effectiveness and cardiovascular protection. Although these diuretics are chemically, pharmacokinetically and pharmacodynamically different, CTD continues to be ...
Source: Drugs of Today - April 14, 2021 Category: Drugs & Pharmacology Authors: S G Chrysant G S Chrysant Source Type: research

Title
Drugs Today (Barc). 2021 Apr;57(4):0. doi: 10.1358/dot.2021.57.4.0000000.ABSTRACTXXX.PMID:33851693 | DOI:10.1358/dot.2021.57.4.0000000 (Source: Drugs of Today)
Source: Drugs of Today - April 14, 2021 Category: Drugs & Pharmacology Authors: X X Author Source Type: research

Update on nifurtimox for treatment of Chagas disease
Drugs Today (Barc). 2021 Apr;57(4):251-263. doi: 10.1358/dot.2021.57.4.3251712.ABSTRACTChagas disease is a vector-borne neglected tropical disease caused by Trypanosoma cruzi. It is a systemic and chronic parasitic infection which is endemic in 21 countries with 10 million cases worldwide and 12,000 annual deaths. Around 70 million people in the Americas are at risk of contracting this disease, and less than 1% of infected people are treated due to low disease awareness and limited access to treatment. The current treatment for Chagas disease consists of benznidazole and nifurtimox under the World Health Organization (WHO)...
Source: Drugs of Today - April 14, 2021 Category: Drugs & Pharmacology Authors: R Thakare A Dasgupta S Chopra Source Type: research